Predict your next investment

HEALTHCARE | Drug Development
antegrin.com

See what CB Insights has to offer

Founded Year

2014

Stage

Merger | Merged

Total Raised

$700K

About Antegrin Therapeutics

Antegrin Therapeutics is a pharmaceutical company dedicated to the development of novel therapies for fibrotic diseases, and offers a robust portfolio of small-molecule integrin antagonists.

Antegrin Therapeutics Headquarter Location

4320 Forest Park Avenue Suite 304

St. Louis, Missouri, 63108,

United States

314-932-4032

Latest Antegrin Therapeutics News

Indalo Therapeutics Formed by Merger of Antegrin and Cascadia

Oct 18, 2016

Transaction Brings Together Groundbreaking Preclinical Assets and Outstanding Drug-Development Expertise ST. LOUIS–(BUSINESS WIRE)–Antegrin Therapeutics and Cascadia Therapeutics today announced the formation of Indalo Therapeutics, a biotechnology company dedicated to developing novel therapies to treat fibrotic diseases. The entity results from the merger of Antegrin and Cascadia and the consolidation of their respective management teams. Financial… Read More »» Committed to Innovation Indalo Therapeutics is a preclinical-stage biotechnology company dedicated to translating groundbreaking scientific discoveries into novel therapies for fibrotic diseases. Our approach is based on cutting-edge research elucidating the central role played by integrin proteins in aberrant fibrotic responses. The company’s lead program is focused on an oral treatment for solid organ fibrosis, which encompasses an array of progressive and debilitating conditions that currently have few FDA-approved medications. Committed to Patients Fibrotic diseases collectively afflict millions of people around the world and are characterized by high rates of morbidity and mortality. These patients are Indalo’s inspiration, and our mission is to improve their lives by developing therapies that arrest or reverse their fibrosis. Our team includes veteran executives who have experienced firsthand the satisfaction of bringing hope to patients suffering from chronic fibrotic diseases through the successful development and approval of an innovative drug for pulmonary fibrosis. More Information 4320 Forest Park Ave., Ste. 304 St. Louis, MO 63108

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Antegrin Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Antegrin Therapeutics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.